help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chon, B. H.
Right arrow Articles by Loeffler, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chon, B. H.
Right arrow Articles by Loeffler, J. S.
The Oncologist, Vol. 7, No. 2, 136-143, April 2002
© 2002 AlphaMed Press

The Effect of Nonmalignant Systemic Disease on Tolerance to Radiation Therapy

Brian H. Chon, Jay S. Loeffler

Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA

Correspondence: Jay S. Loeffler, M.D., Massachusetts General Hospital, Department of Radiation Oncology, 100 Blossom Street, Boston, Massachusetts 02114, USA. Telephone: 617-726-8653; Fax: 617-726-3603; e-mail: jloeffler{at}partners.org

Purpose. Some patients with nonmalignant systemic diseases, like collagen vascular disease (CVD), hypertension, diabetes mellitus, and inflammatory bowel disease (IBD), tolerate radiation therapy poorly. Although the mechanisms of each of these disease processes are different, they share a common microvessel pathology that is potentially exacerbated by radiotherapy. This article reviews and evaluates available data examining the effects of these benign disease processes on radiation tolerance.

Methods. We conducted a thorough review of the Anglo-American medical literature from 1960 to 2001 on the effects of radiotherapy on CVD, hypertension, diabetes mellitus, and IBD.

Results. Fifteen studies were identified that examined the effects of radiation therapy for cancer in patients with CVDs. Thirteen of 15 studies documented greater occurrences of acute and late toxicities (range 7%-100%). Higher rates of complications were noted especially for nonrheumatoid arthritis CVDs. Nine studies evaluated the effects of hypertension and diabetes on radiation tolerance. All nine studies documented higher rates of late toxicities than in a "control" group (range 34%-100%). When patients had both diabetes and hypertension, the risk of late toxicities was even higher. Six studies examined radiation tolerance of patients with IBD irradiated to the abdomen and pelvis. Five of these six studies showed greater occurrences of acute and late toxicities for patients with IBD, even with precautionary measures like reduced fraction size and volume and patient immobilization (13%-29%).

Conclusion. The majority of published studies documented lower radiation tolerance for patients who have CVD, diabetes mellitus, hypertension, and IBD. This may reflect a publication bias, as the majority of these studies are retrospective with small numbers of patients and use different scoring scales for complications. These factors may contribute to an overestimation of true radiation-induced morbidity. Although the paucity of data makes precise estimates difficult, a subset of patients, in particular, those with active CVD, IBD, or a combination of uncontrolled hypertension with type I diabetes, is likely to be at higher risk. Future prospective trials need to document these disease entities when reporting treatment-related complications and also must monitor toxicities associated with quiescent versus active IBD and CVD, type I versus type II diabetes, and levels of hypertension (controlled versus uncontrolled) matched for radiation-specific treatment sites, field size, fractionation, and total dose.

Key Words. Collagen vascular disease • Hypertension • Diabetes • Inflammatory bowel disease • Radiation therapy




This article has been cited by other articles:


Home page
NEJMHome page
T. M. Pisansky
External-beam radiotherapy for localized prostate cancer.
N. Engl. J. Med., October 12, 2006; 355(15): 1583 - 1591.
[Full Text] [PDF]


Home page
JCOHome page
T. J. Whelan
Use of Conventional Radiation Therapy As Part of Breast-Conserving Treatment
J. Clin. Oncol., March 10, 2005; 23(8): 1718 - 1725.
[Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
K. E. Rieger, W.-J. Hong, V. G. Tusher, J. Tang, R. Tibshirani, and G. Chu
Toxicity from radiation therapy associated with abnormal transcriptional responses to DNA damage
PNAS, April 27, 2004; 101(17): 6635 - 6640.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2002 by AlphaMed Press.